WASHINGTON (Reuters) - AstraZeneca Plc’s cancer pill Recentin, developed to be a rival to the blockbuster Avastin, may help fight the deadly effects of brain tumors without shrinking them, researchers reported on Monday.
WASHINGTON (Reuters) - AstraZeneca Plc’s cancer pill Recentin, developed to be a rival to the blockbuster Avastin, may help fight the deadly effects of brain tumors without shrinking them, researchers reported on Monday.
